Noah Hahn, MD
Enriched profileCo-Director, Greenberg Bladder Cancer Institute; Director, Medical Oncology Bladder Cancer Program; Professor of Oncology and Urology, Johns Hopkins University School of Medicine · Johns Hopkins University School of Medicine
Noah Hahn is Co-Director, Greenberg Bladder Cancer Institute; Director, Medical Oncology Bladder Cancer Program; Professor of Oncology and Urology, Johns Hopkins University School of Medicine at Johns Hopkins University School of Medicine. OpenAlex indexes 586 publications with 18,563 citations (h-index 58); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Noah Hahn, M.D., is Co-Director, Greenberg Bladder Cancer Institute at Johns Hopkins University School of Medicine. The public record shows 586 publications with 18,563 citations (h-index 58), centered on Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2019–2024).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Bladder and Urothelial Cancer Treatments
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 164.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 16 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20258 payments
- PFIZER INC.Program year20253 payments
- Astellas Pharma US IncProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86.9%Other monoclonal antibodies and antibody drug conjugates55%Enfortumab vedotin-ejfv100%Part B, office-administered≥13 patientsPD-1 inhibitor31.3%Pembrolizumab100%Part B, office-administered≥20 patients+ 1 more class in this area
Metabolism & gastrointestinal
12.1%Other antiemetics9.9%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist2.2%Ondansetron hydrochloride100%Part B, office-administered≥27 patients+ 1 more class in this area
Sensory organs
0.8%Corticosteroid0.8%Dexamethasone sodium phosphate100%Part B, office-administered≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2019–2024 per NIH RePORTER. The latest:
- Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
Johns Hopkins University
FY2024$243,567R01CA235681 - Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
Johns Hopkins University
FY2023$597,082R01CA235681 - Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
Johns Hopkins University
FY2022$628,148R01CA235681
Congress activity
Updated 16 Oct 2026
136 congress contributions (2005–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.
Clinical cancer research
Clinical Trial2026 - Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin-Related Dermatologic Events in Patients with Advanced Urothelial Cancer.
Cancer research communications
Article2025 - Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer().
Bladder cancer (Amsterdam, Netherlands)
Review2025 - A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Clinical cancer research
Clinical Trial2025 - A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Clinical cancer research
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerArticle2,863 citations2015
- 02Bladder cancerArticle1,466 citations2016
- 03
- 04
- 05Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaArticle848 citations2017
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/noah-hahn-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
bcan.org/staff/noah-m-hahn-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Other
hopkinsmedicine.org/greenberg-bladder-cancer-institute/about-bladder-cancer/virtual-grand-rounds
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗ - X / Twitter
x.com/jhbladdercancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Bladder Cancer Subcommittee, Eastern Cooperative Oncology Group (ECOG)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗ - Member
Bladder Cancer Task Force, National Cancer Institute Genitourinary Cancer Steering Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗ - Member
Scientific Advisory Board, Bladder Cancer Advocacy Network
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗
Media & interviews
press, podcasts and appearances- Video lecture
"Immuno-Oncology in Bladder Cancer: The Urologist's Role," UroToday
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)